Answer
Women of childbearing potential and men with female partners of childbearing potential should use effective contraception during pemigatinib treatment and for one week afterward, adding a barrier method as a second form because contraceptive effects are unstudied; women should avoid pregnancy and men should not father a child during treatment.
Sources for this answer
- Pemazyre 4.5 mg - tabletsIncyte Biosciences UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 5Document updated
Sources checked